The increase in proportion of CD45+ cells after BLS treatment at day 2 could be visualized by imaging fluorescently labelled CD45+ cells in precision cut tumor slices (Fig. 2C) and quantified (Fig. 2D). The gene discussed is PTPRC; the disease is neoplasm.